Editorial
doi: 10.1200/JCO.2009.24.8021.
Epub 2009 Nov 30.
Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?
- PMID: 19949009
- DOI: 10.1200/JCO.2009.24.8021
Item in Clipboard
Editorial
Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?
J Clin Oncol.
.
No abstract available
Comment on
-
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.J Clin Oncol. 2010 Jan 10;28(2):207-14. doi: 10.1200/JCO.2009.22.9237. Epub 2009 Nov 30. J Clin Oncol. 2010. PMID: 19949018 Free PMC article. Clinical Trial.
-
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.J Clin Oncol. 2010 Jan 10;28(2):193-201. doi: 10.1200/JCO.2009.22.4279. Epub 2009 Nov 30. J Clin Oncol. 2010. PMID: 19949019 Free PMC article. Clinical Trial.
Similar articles
-
Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.Med Oncol. 2016 Oct;33(10):105. doi: 10.1007/s12032-016-0824-y. Epub 2016 Aug 27. Med Oncol. 2016. PMID: 27568331
-
Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3453. doi: 10.1073/pnas.1506689112. Epub 2015 Jun 16. Proc Natl Acad Sci U S A. 2015. PMID: 26080431 Free PMC article. No abstract available.
-
Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3454. doi: 10.1073/pnas.1507225112. Epub 2015 Jun 16. Proc Natl Acad Sci U S A. 2015. PMID: 26080434 Free PMC article. No abstract available.
-
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.Clin Lung Cancer. 2008;9 Suppl 3:S100-8. doi: 10.3816/CLC.2008.s.015. Clin Lung Cancer. 2008. PMID: 19419923 Review.
-
Chemotherapy and antiangiogenic agents in non-small-cell lung cancer.Clin Lung Cancer. 2007 Feb;8 Suppl 2:S68-73. doi: 10.3816/clc.2007.s.004. Clin Lung Cancer. 2007. PMID: 17382027 Review.
Cited by
-
Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer.Clin Transl Oncol. 2010 Aug;12(8):521-5. doi: 10.1007/s12094-010-0549-x. Clin Transl Oncol. 2010. PMID: 20709649 Review.
-
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.Oncotarget. 2016 Apr 5;7(14):18531-40. doi: 10.18632/oncotarget.7612. Oncotarget. 2016. PMID: 26921265 Free PMC article. Clinical Trial.
-
Controlling escape from angiogenesis inhibitors.Nat Rev Cancer. 2012 Oct;12(10):699-709. doi: 10.1038/nrc3366. Nat Rev Cancer. 2012. PMID: 23001349 Free PMC article. Review.
-
Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.Neuro Oncol. 2014 Mar;16(3):392-9. doi: 10.1093/neuonc/not226. Epub 2013 Dec 9. Neuro Oncol. 2014. PMID: 24327581 Free PMC article.
-
Obesity and Cancer: An Angiogenic and Inflammatory Link.Microcirculation. 2016 Apr;23(3):191-206. doi: 10.1111/micc.12270. Microcirculation. 2016. PMID: 26808917 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
